Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH.
Bataller R, Cabezas J, Aller R, Ventura-Cots M, Abad J, Albillos A, Altamirano J, Arias-Loste MT, Bañares R, Caballería J, Caballería L, Carrión JA, Diago M, Fernández Rodríguez C, Gallego R, García-Cortes M, García-Monzón C, Genescà J, Ginés P, Hernandez-Guerra M, Jorquera F, Lligoña A, Molina E, Pareja MJ, Planas R, Tomé S, Salmerón J, Romero-Gómez M. Bataller R, et al. Among authors: fernandez rodriguez c. Gastroenterol Hepatol. 2019 Dec;42(10):657-676. doi: 10.1016/j.gastrohep.2019.09.006. Epub 2019 Nov 23. Gastroenterol Hepatol. 2019. PMID: 31771785 English, Spanish.
The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement.
Aller R, de Luis DA, Moreira V, Boixeda D, Moya JL, Fernandez-Rodriguez CM, San Román AL, Avila S, Bárcena R. Aller R, et al. Among authors: fernandez rodriguez cm. J Endocrinol Invest. 2001 Jul-Aug;24(7):503-9. doi: 10.1007/BF03343883. J Endocrinol Invest. 2001. PMID: 11508784 Clinical Trial.
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: fernandez rodriguez cm. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
[Treatment optimization in chronic hepatitis C virus infection].
Fernández Rodríguez CM, Alonso López S. Fernández Rodríguez CM, et al. Gastroenterol Hepatol. 2010 Feb;33(2):119-25. doi: 10.1016/j.gastrohep.2009.07.001. Epub 2009 Oct 4. Gastroenterol Hepatol. 2010. PMID: 19804920 Review. Spanish.
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Fernández-Rodríguez CM, et al. Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700116
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M. Fernández-Rodríguez CM, et al. Gastroenterol Hepatol. 2014 Jan;37(1):1-8. doi: 10.1016/j.gastrohep.2013.10.005. Epub 2013 Dec 17. Gastroenterol Hepatol. 2014. PMID: 24360571 Clinical Trial.
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis. Calleja JL, et al. Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15. Liver Int. 2015. PMID: 25113158 Clinical Trial.
243 results